Merck (MRK) Goodwill & Intangibles (2009 - 2026)
Merck (MRK) posted quarterly Goodwill & Intangibles of $47.3 billion for Q1 2026, up 26.4% YoY from $37.4 billion in Q1 2025, and down 1.94% sequentially from $48.3 billion in Q4 2025.
Merck (MRK) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Merck has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $47.3 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 26.4% year-over-year to $47.3 billion; the TTM figure through Mar 2026 stood at $47.3 billion (up 26.4% YoY), while the FY2025 annual figure was $48.3 billion, up 26.87% from the prior year.
- Goodwill & Intangibles declined to $47.3 billion in Q1 2026, from $48.3 billion in the prior quarter.
- Over the last five years, Goodwill & Intangibles for MRK reached as high as $48.3 billion in Q4 2025 and fell as low as $36.8 billion in Q2 2025.
- The 5-year median for Goodwill & Intangibles is $40.4 billion (2023), against an average of $40.8 billion.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles soared 34.51% — and 2023, when it decreased 7.26%.
- A 5-year view of Goodwill & Intangibles shows it stood at $41.5 billion in 2022, then declined by 5.46% to $39.2 billion in 2023, then decreased by 2.98% to $38.0 billion in 2024, then rose by 26.87% to $48.3 billion in 2025, then dropped by 1.94% to $47.3 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $47.3 billion, $48.3 billion, and $36.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.33 Bn |
| Dec 31, 2025 | 48.26 Bn |
| Sep 30, 2025 | 36.90 Bn |
| Jun 30, 2025 | 36.78 Bn |
| Mar 31, 2025 | 37.44 Bn |
| Dec 31, 2024 | 38.04 Bn |
| Sep 30, 2024 | 38.71 Bn |
| Jun 30, 2024 | 38.15 Bn |
| Mar 31, 2024 | 38.75 Bn |
| Dec 31, 2023 | 39.21 Bn |
| Sep 30, 2023 | 40.38 Bn |
| Jun 30, 2023 | 40.86 Bn |
| Mar 31, 2023 | 41.07 Bn |
| Dec 31, 2022 | 41.47 Bn |
| Sep 30, 2022 | 42.53 Bn |
| Jun 30, 2022 | 43.71 Bn |
| Mar 31, 2022 | 44.28 Bn |
| Dec 31, 2021 | 44.20 Bn |
| Sep 30, 2021 | 32.25 Bn |
| Jun 30, 2021 | 32.50 Bn |